Table 1.
Open in new tab

Demographic and Clinical Characteristics of the Cohort Stratified Between Patients With NPTDM and PTDM

PTDM (n = 40)NPTDM (n = 51)P
Female, n (%)24 (60)15 (29.4)0.017
Age, y, mean (± SD)
 At transplantation49 (10.9)40 (11.8)0.001
 Current58 (10.6)50 (11.1)0.002
Transplantation time, y, mean (± SD)8.5 (3.05)8.94 (3.44)0.525
Weight, kg, mean (± SD)
 At transplantation75.2 (13.4)66.3 (14.2)0.005
 Current75.09 (13.7)74.54 (10.8)0.834
BMI, kg/m2 (± SD)
 At transplantation28.1 (4.3)24.2 (4.9)0.001
 Current28.38 (4.81)27.08 (4.06)0.222
Caucasian, n (%)32 (80)40 (78.4)1.00
Polycystic kidney disease, n (%)11 (27.5)4 (7.8)0.026
Hypertension19 (47.5)19 (37.2)0.442
 Preoperative history, n (%)
Current smoking, n (%)4 (10)6 (11.7)1.00
Parental DM, n (%)16 (40)22 (43.2)0.931
Pretransplant dialysis, n (%)39 (97.5)48 (94.2)0.628
Dialysis time, mo, median (IQR)35 (53)23 (47)0.162
Positive HCV status, n (%)4 (10)6 (12)1.00
Deceased donor, n (%)31 (77)35 (66.5)0.367
Donor age, y, mean (± SD)37.11 (13.84)41.33 (13.54)0.173
Donor sex, male, n (%)18 (45)23 (51.1)0.730
Cold ischemic time, min, median (IQR)1095 (1399)840 (1260)0.138
Delayed graft function, n (%)a24 (29)14 (20.7)0.122
Acute rejection, n (%)b8 (9.6)12 (14.5)0.559
Current use of antihypertensive drug, n (%)33 (82.5)39 (76.5)0.658
Number of antihypertensive, median (IQR)2 (2)1 (2)0.148
ACEI use, n (%)11 (27.5)15 (29.4)1.000
ARB use, n (%)5 (12.5)3 (5.9)0.463
Blood pressure, mm Hg
 Systolic134.4 (15.2)138.6 (18.8)0.389
 Diastolic85.7 (17.5)82.2 (10.3)0.397
Current immunosuppressants, n (%)
 Tacrolimus26 (65)29 (56.8)0.567
 Cyclosporine8 (20)16 (31.3)0.326
 Prednisone39 (97.5)51 (100)0.440
 Mycophenolate mofetil27 (67.5)44 (86.3)0.059
 Azathioprine2 (5)2 (3.9)1.00
 Sirolimus4 (10)5 (9.8)1.00
Tacrolimus, serum level, mg/dL mean (± SD)
 Day 10 after transplant10.9 (3.5)11.5 (4.5)0.630
 Day 30 after transplant11.8 (4.6)10.6 (3.6)0.284
 Higher (first 90 d)20.4 (5.4)22.2 (5.8)0.269
 Current6.09 (2.6)
Fasting plasma glucose, mg/dL, median (IQR)
 At transplantation91.5 (27)89 (11)0.123
 Current118 (41)92 (20)<0.001
GHb (%)
 Current, median (IQR)7.0 (1.7)5.60 (0.6)<0.001
 All available, mean (± SD)7.4 (1.3)5.47 (0.6)<0.001
Total cholesterol, mg/dL, mean (± SD)
 At transplantation202.1 (50.8)181.6 (38.1)0.085
 Current193.4 (43.4)192.2 (49.1)0.905
Triglycerides, mg/dL, median (IQR)
 At transplantation177 (101)151 (128)0.089
 Current166 (136)140.5 (68)0.114
PTDM (n = 40)NPTDM (n = 51)P
Female, n (%)24 (60)15 (29.4)0.017
Age, y, mean (± SD)
 At transplantation49 (10.9)40 (11.8)0.001
 Current58 (10.6)50 (11.1)0.002
Transplantation time, y, mean (± SD)8.5 (3.05)8.94 (3.44)0.525
Weight, kg, mean (± SD)
 At transplantation75.2 (13.4)66.3 (14.2)0.005
 Current75.09 (13.7)74.54 (10.8)0.834
BMI, kg/m2 (± SD)
 At transplantation28.1 (4.3)24.2 (4.9)0.001
 Current28.38 (4.81)27.08 (4.06)0.222
Caucasian, n (%)32 (80)40 (78.4)1.00
Polycystic kidney disease, n (%)11 (27.5)4 (7.8)0.026
Hypertension19 (47.5)19 (37.2)0.442
 Preoperative history, n (%)
Current smoking, n (%)4 (10)6 (11.7)1.00
Parental DM, n (%)16 (40)22 (43.2)0.931
Pretransplant dialysis, n (%)39 (97.5)48 (94.2)0.628
Dialysis time, mo, median (IQR)35 (53)23 (47)0.162
Positive HCV status, n (%)4 (10)6 (12)1.00
Deceased donor, n (%)31 (77)35 (66.5)0.367
Donor age, y, mean (± SD)37.11 (13.84)41.33 (13.54)0.173
Donor sex, male, n (%)18 (45)23 (51.1)0.730
Cold ischemic time, min, median (IQR)1095 (1399)840 (1260)0.138
Delayed graft function, n (%)a24 (29)14 (20.7)0.122
Acute rejection, n (%)b8 (9.6)12 (14.5)0.559
Current use of antihypertensive drug, n (%)33 (82.5)39 (76.5)0.658
Number of antihypertensive, median (IQR)2 (2)1 (2)0.148
ACEI use, n (%)11 (27.5)15 (29.4)1.000
ARB use, n (%)5 (12.5)3 (5.9)0.463
Blood pressure, mm Hg
 Systolic134.4 (15.2)138.6 (18.8)0.389
 Diastolic85.7 (17.5)82.2 (10.3)0.397
Current immunosuppressants, n (%)
 Tacrolimus26 (65)29 (56.8)0.567
 Cyclosporine8 (20)16 (31.3)0.326
 Prednisone39 (97.5)51 (100)0.440
 Mycophenolate mofetil27 (67.5)44 (86.3)0.059
 Azathioprine2 (5)2 (3.9)1.00
 Sirolimus4 (10)5 (9.8)1.00
Tacrolimus, serum level, mg/dL mean (± SD)
 Day 10 after transplant10.9 (3.5)11.5 (4.5)0.630
 Day 30 after transplant11.8 (4.6)10.6 (3.6)0.284
 Higher (first 90 d)20.4 (5.4)22.2 (5.8)0.269
 Current6.09 (2.6)
Fasting plasma glucose, mg/dL, median (IQR)
 At transplantation91.5 (27)89 (11)0.123
 Current118 (41)92 (20)<0.001
GHb (%)
 Current, median (IQR)7.0 (1.7)5.60 (0.6)<0.001
 All available, mean (± SD)7.4 (1.3)5.47 (0.6)<0.001
Total cholesterol, mg/dL, mean (± SD)
 At transplantation202.1 (50.8)181.6 (38.1)0.085
 Current193.4 (43.4)192.2 (49.1)0.905
Triglycerides, mg/dL, median (IQR)
 At transplantation177 (101)151 (128)0.089
 Current166 (136)140.5 (68)0.114

Significant P values appear in in bold-face type.

Abbreviations: ACE, angiotensin-converting enzyme inhibitor; BMI, body mass index; HCV, hepatitis C virus.

a

n = 82.

b

n = 83.

Table 1.
Open in new tab

Demographic and Clinical Characteristics of the Cohort Stratified Between Patients With NPTDM and PTDM

PTDM (n = 40)NPTDM (n = 51)P
Female, n (%)24 (60)15 (29.4)0.017
Age, y, mean (± SD)
 At transplantation49 (10.9)40 (11.8)0.001
 Current58 (10.6)50 (11.1)0.002
Transplantation time, y, mean (± SD)8.5 (3.05)8.94 (3.44)0.525
Weight, kg, mean (± SD)
 At transplantation75.2 (13.4)66.3 (14.2)0.005
 Current75.09 (13.7)74.54 (10.8)0.834
BMI, kg/m2 (± SD)
 At transplantation28.1 (4.3)24.2 (4.9)0.001
 Current28.38 (4.81)27.08 (4.06)0.222
Caucasian, n (%)32 (80)40 (78.4)1.00
Polycystic kidney disease, n (%)11 (27.5)4 (7.8)0.026
Hypertension19 (47.5)19 (37.2)0.442
 Preoperative history, n (%)
Current smoking, n (%)4 (10)6 (11.7)1.00
Parental DM, n (%)16 (40)22 (43.2)0.931
Pretransplant dialysis, n (%)39 (97.5)48 (94.2)0.628
Dialysis time, mo, median (IQR)35 (53)23 (47)0.162
Positive HCV status, n (%)4 (10)6 (12)1.00
Deceased donor, n (%)31 (77)35 (66.5)0.367
Donor age, y, mean (± SD)37.11 (13.84)41.33 (13.54)0.173
Donor sex, male, n (%)18 (45)23 (51.1)0.730
Cold ischemic time, min, median (IQR)1095 (1399)840 (1260)0.138
Delayed graft function, n (%)a24 (29)14 (20.7)0.122
Acute rejection, n (%)b8 (9.6)12 (14.5)0.559
Current use of antihypertensive drug, n (%)33 (82.5)39 (76.5)0.658
Number of antihypertensive, median (IQR)2 (2)1 (2)0.148
ACEI use, n (%)11 (27.5)15 (29.4)1.000
ARB use, n (%)5 (12.5)3 (5.9)0.463
Blood pressure, mm Hg
 Systolic134.4 (15.2)138.6 (18.8)0.389
 Diastolic85.7 (17.5)82.2 (10.3)0.397
Current immunosuppressants, n (%)
 Tacrolimus26 (65)29 (56.8)0.567
 Cyclosporine8 (20)16 (31.3)0.326
 Prednisone39 (97.5)51 (100)0.440
 Mycophenolate mofetil27 (67.5)44 (86.3)0.059
 Azathioprine2 (5)2 (3.9)1.00
 Sirolimus4 (10)5 (9.8)1.00
Tacrolimus, serum level, mg/dL mean (± SD)
 Day 10 after transplant10.9 (3.5)11.5 (4.5)0.630
 Day 30 after transplant11.8 (4.6)10.6 (3.6)0.284
 Higher (first 90 d)20.4 (5.4)22.2 (5.8)0.269
 Current6.09 (2.6)
Fasting plasma glucose, mg/dL, median (IQR)
 At transplantation91.5 (27)89 (11)0.123
 Current118 (41)92 (20)<0.001
GHb (%)
 Current, median (IQR)7.0 (1.7)5.60 (0.6)<0.001
 All available, mean (± SD)7.4 (1.3)5.47 (0.6)<0.001
Total cholesterol, mg/dL, mean (± SD)
 At transplantation202.1 (50.8)181.6 (38.1)0.085
 Current193.4 (43.4)192.2 (49.1)0.905
Triglycerides, mg/dL, median (IQR)
 At transplantation177 (101)151 (128)0.089
 Current166 (136)140.5 (68)0.114
PTDM (n = 40)NPTDM (n = 51)P
Female, n (%)24 (60)15 (29.4)0.017
Age, y, mean (± SD)
 At transplantation49 (10.9)40 (11.8)0.001
 Current58 (10.6)50 (11.1)0.002
Transplantation time, y, mean (± SD)8.5 (3.05)8.94 (3.44)0.525
Weight, kg, mean (± SD)
 At transplantation75.2 (13.4)66.3 (14.2)0.005
 Current75.09 (13.7)74.54 (10.8)0.834
BMI, kg/m2 (± SD)
 At transplantation28.1 (4.3)24.2 (4.9)0.001
 Current28.38 (4.81)27.08 (4.06)0.222
Caucasian, n (%)32 (80)40 (78.4)1.00
Polycystic kidney disease, n (%)11 (27.5)4 (7.8)0.026
Hypertension19 (47.5)19 (37.2)0.442
 Preoperative history, n (%)
Current smoking, n (%)4 (10)6 (11.7)1.00
Parental DM, n (%)16 (40)22 (43.2)0.931
Pretransplant dialysis, n (%)39 (97.5)48 (94.2)0.628
Dialysis time, mo, median (IQR)35 (53)23 (47)0.162
Positive HCV status, n (%)4 (10)6 (12)1.00
Deceased donor, n (%)31 (77)35 (66.5)0.367
Donor age, y, mean (± SD)37.11 (13.84)41.33 (13.54)0.173
Donor sex, male, n (%)18 (45)23 (51.1)0.730
Cold ischemic time, min, median (IQR)1095 (1399)840 (1260)0.138
Delayed graft function, n (%)a24 (29)14 (20.7)0.122
Acute rejection, n (%)b8 (9.6)12 (14.5)0.559
Current use of antihypertensive drug, n (%)33 (82.5)39 (76.5)0.658
Number of antihypertensive, median (IQR)2 (2)1 (2)0.148
ACEI use, n (%)11 (27.5)15 (29.4)1.000
ARB use, n (%)5 (12.5)3 (5.9)0.463
Blood pressure, mm Hg
 Systolic134.4 (15.2)138.6 (18.8)0.389
 Diastolic85.7 (17.5)82.2 (10.3)0.397
Current immunosuppressants, n (%)
 Tacrolimus26 (65)29 (56.8)0.567
 Cyclosporine8 (20)16 (31.3)0.326
 Prednisone39 (97.5)51 (100)0.440
 Mycophenolate mofetil27 (67.5)44 (86.3)0.059
 Azathioprine2 (5)2 (3.9)1.00
 Sirolimus4 (10)5 (9.8)1.00
Tacrolimus, serum level, mg/dL mean (± SD)
 Day 10 after transplant10.9 (3.5)11.5 (4.5)0.630
 Day 30 after transplant11.8 (4.6)10.6 (3.6)0.284
 Higher (first 90 d)20.4 (5.4)22.2 (5.8)0.269
 Current6.09 (2.6)
Fasting plasma glucose, mg/dL, median (IQR)
 At transplantation91.5 (27)89 (11)0.123
 Current118 (41)92 (20)<0.001
GHb (%)
 Current, median (IQR)7.0 (1.7)5.60 (0.6)<0.001
 All available, mean (± SD)7.4 (1.3)5.47 (0.6)<0.001
Total cholesterol, mg/dL, mean (± SD)
 At transplantation202.1 (50.8)181.6 (38.1)0.085
 Current193.4 (43.4)192.2 (49.1)0.905
Triglycerides, mg/dL, median (IQR)
 At transplantation177 (101)151 (128)0.089
 Current166 (136)140.5 (68)0.114

Significant P values appear in in bold-face type.

Abbreviations: ACE, angiotensin-converting enzyme inhibitor; BMI, body mass index; HCV, hepatitis C virus.

a

n = 82.

b

n = 83.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close